Dare Bioscience (Dare Bioscience) Ending Cash Position : $3.97 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience Ending Cash Position?

Dare Bioscience's Ending Cash Position for the quarter that ended in Mar. 2024 was $3.97 Mil.

Dare Bioscience's quarterly Ending Cash Position declined from Sep. 2023 ($14.23 Mil) to Dec. 2023 ($10.81 Mil) and declined from Dec. 2023 ($10.81 Mil) to Mar. 2024 ($3.97 Mil).

Dare Bioscience's annual Ending Cash Position declined from Dec. 2021 ($51.67 Mil) to Dec. 2022 ($34.67 Mil) and declined from Dec. 2022 ($34.67 Mil) to Dec. 2023 ($10.81 Mil).

Dare Bioscience Ending Cash Position Historical Data

The historical data trend for Dare Bioscience's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience Ending Cash Position Chart

Dare Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

4.78

4.67

51.67

34.67

10.81

Dare Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															19.83	13.66	14.23	10.81	3.97

Dare Bioscience Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Dare Bioscience's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	34.67	+	-23.859
	=	10.81

Dare Bioscience's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	10.811	+	-6.845
	=	3.97

Dare Bioscience Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Dare Bioscience (Dare Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122

Website

https://www.darebioscience.com

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Executives

Sophia Nnenna Ononye-onyia	director	1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson	director, officer: Chef Executive Officer	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair	officer: Chief Strategy Officer	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley	director	3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz	director	1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman	director	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert	officer: Chief Financial Officer	C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof	officer: SVP, Chief Scientific Officer	C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz	officer: SVP, Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle	director	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal	officer: VP, General Counsel	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill	officer: Principal Accounting Officer	15 GREENBRIAR CIRCLE, ANDOVER MA 01810